PD-1 Immunotherapy Shows Promise for Liver Cancer but Needs Better Patient Selection

Hepatocellular carcinoma represents a major global health challenge as the sixth most common cancer and third leading cause of cancer-related deaths worldwide. The late-stage diagnosis typical of HCC patients often precludes surgical intervention, historically limiting treatment options to targeted therapies like sorafenib and lenvatinib.

The emergence of immunotherapy, particularly immune checkpoint inhibitors targeting the PD-1/PD-L1 pathway, has revolutionized HCC treatment approaches. These therapies work by removing the brakes on the immune system, allowing it to better recognize and attack cancer cells. Both single-agent immunotherapies and combination regimens have shown clinical promise.

However, a critical limitation remains: not all HCC patients respond to immunotherapy. This variability in treatment response highlights the urgent need for predictive biomarkers that can identify which patients are most likely to benefit from these expensive and potentially toxic treatments.

This review synthesizes current research on immunotherapy for HCC, examining both efficacy and safety profiles. The authors emphasize the clinical importance of developing reliable markers to predict treatment outcomes and identify patients at risk for immune-related adverse events. Such biomarkers could significantly improve treatment selection and patient outcomes while reducing unnecessary exposure to ineffective therapies.